Media headlines about Molecular Templates (NASDAQ:MTEM) have trended somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Molecular Templates earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.9964360151274 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- Molecular Templates (MTEM) Announces Quarterly Earnings Results (americanbankingnews.com)
- Molecular Templates misses by $0.11 (seekingalpha.com)
- Molecular Templates, Inc. Reports Second Quarter 2018 Financial Results (finance.yahoo.com)
- Global Hodgkin Lymphoma Treatment Market Outlook 2018: Cell Medica Limited, Cellular Biomedicine Group, Inc. (marketglobalnews.com)
- Leap Therapeutics, Inc. (LPTX) Top Loser to observe: (topdesertsafari.com)
MTEM has been the topic of several research analyst reports. ValuEngine cut shares of Molecular Templates from a “hold” rating to a “sell” rating in a research note on Friday, July 6th. Zacks Investment Research upgraded shares of Molecular Templates from a “sell” rating to a “hold” rating in a research note on Thursday, June 7th.
Shares of Molecular Templates traded up $0.03, hitting $5.33, during trading on Friday, Marketbeat.com reports. The company’s stock had a trading volume of 39,291 shares, compared to its average volume of 68,419. Molecular Templates has a 12 month low of $4.61 and a 12 month high of $13.25. The company has a quick ratio of 4.54, a current ratio of 4.54 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $143.42 million, a PE ratio of -2.53 and a beta of 3.05.
Molecular Templates (NASDAQ:MTEM) last issued its quarterly earnings data on Thursday, August 9th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.61. Molecular Templates had a negative net margin of 509.53% and a negative return on equity of 21.47%. The firm had revenue of $1.37 million for the quarter. analysts expect that Molecular Templates will post -1.17 earnings per share for the current fiscal year.
Molecular Templates Company Profile
Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase I clinical trial for the treatment of relapsed/refractory non-Hodgkin's lymphoma and B-cell lymphoma.
Featured Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.